2Baxendale A,Bountra C,Clayton N, et al. Irritable bowel syndrome as visceral hyperalgesia:implications for therapy[J]. Curr Opin CPNS Invest Drug, 1999,1(1):86.
3O'Sullivan MA, Mallmud N, Kelleher DP, et al. Patient knowledge and educational needs in irritable bowel syndrome[J]. Eur J Gastroent Crol Hepatol,2000,12:39.
4Colwell LJ,Prather CM,Phillips SF, et al. Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms[J]. Am J Gastroenterol,1998,93:901.
5Simren M, Mansson A, Largkide AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome[J]. Digestion,2001,63:108.
6Efskind PS,Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome[J]. Scand J Gastroenterol, 1996,31:463.
7Houghton LA, Rogers J ,Whorwell PJ. Zamifenacin (UK-76,654) a potent gut M3 selective muscarinic antagonist,reduces colonic motor activity in patients with irritable bowel syndrome[J]. Aliment Pharmacol Ther, 1997,11:561.
8Wittmann T. Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable syndrome[J]. Orv Hetil, 1999,140:469.
9Lu CL,Chen CY,Change FY, et al. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome[J]. J Gastroenterol Hepatol,2000,15(8):925.
10Battaglia G,Morselli-Labate AM,Camarri E, et al. Otilonium bromide in irritable bowel syndrome: a doubleblind,place-controlled, 15-week study[J]. Aliment Pharmacol Ther, 1999,12:1003.
